$505.13-12.27% · 3M
Moving avg
1W-6.26%
1M-5.01%
3M-11.16%
6M+6.64%
YTD+1.69%
1Y+61.87%
3Y+116.55%
5Y+153.24%
52-week range
$272.1269% of range$609.35
Company health
Value2/6
Growth4/6
Profitability6/6
Health6/6
Dividend0/6
Bull vs bear
Strengths
- Analysts see 26% upside to a $635 target
- Analyst consensus is "Buy"
- Strong 42% net margin
- High return on equity (1924%)
- Net cash on the balance sheet
Risks
No obvious red flags from the metrics.
Key statistics
Valuation
Market cap
$21.44B
Enterprise value
$21.36B
P/E ratio (TTM)
18.06x
P/S ratio (TTM)
7.08x
EV/EBITDA
12.46x
Per share & returns
EPS (TTM)
$29.60
Dividend yield
0.00%
Beta (1Y)
0.58
30-day change
-5.01%
Trading
Volume (24h)
100.92K
Previous close
$511.72
Shares outstanding
42.45M
About United Therapeutics Corporation
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Symbol
UTHR
United Therapeutics Corporation is a large-cap healthcare company in the Biotechnology industry. Its shares are listed on NASDAQ (United States) and trade under the ticker UTHR.
Frequently asked questions
What is United Therapeutics Corporation's market cap?
United Therapeutics Corporation (UTHR) has a market capitalization of $21.44B.
What is United Therapeutics Corporation's P/E ratio?
United Therapeutics Corporation trades at a price-to-earnings (P/E) ratio of 18.06.
What exchange does UTHR trade on?
UTHR trades on NASDAQ.
Appears in
Eli Lilly and CompanyLLY
$1,218.31-0.16%
$1.15T cap
Johnson & JohnsonJNJ
$261.30+0.17%
$629.71B cap
AbbVie Inc.ABBV
$250.30+0.62%
$442.23B cap
UnitedHealth Group IncorporatedUNH
$402.11-0.86%
$365.17B cap
Roche Holding AGSWX: ROP
CHF 362.30-0.88%
$355.30B cap
Merck & Co., Inc.MRK
$134.70+1.34%
$332.68B cap
Novartis AGSWX: NOVN
CHF 123.74-0.37%
$289.76B cap
AstraZeneca PLCLON: AZN
£117.08+0.05%
$245.27B cap